Biomarker-Based Immunoassays Market Report 2026

Biomarker-Based Immunoassays Market Overview

• Biomarker-Based Immunoassays market size has reached to $6.6 billion in 2025 • Expected to grow to $11.55 billion in 2030 at a compound annual growth rate (CAGR) of 11.9% • Growth Driver: Increasing Incidence Of Oncology Cases Driving The Market Growth Due To Rising Cancer Burden • Market Trend: Next-Generation Ultrasensitive Immunoassay Platforms Enhance Biomarker Detection Accuracy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biomarker-Based Immunoassays Market?

Biomarker-based immunoassays are analytical techniques that use antigen–antibody interactions to detect and quantify specific biological markers in a sample. These biomarkers can include proteins, hormones, or other molecules that indicate normal or pathological processes within the body. Biomarker-based immunoassays provide highly sensitive and specific measurements, making them essential tools in diagnostics and biomedical research. The main products of biomarker-based immunoassays include consumables, instruments and analyzers, reagents and kits, and services. Consumables refer to disposable laboratory materials used during immunoassay procedures for sample preparation and testing. The different biomarker types include protein biomarkers, hormone biomarkers, cardiac biomarkers, cancer biomarkers, infectious disease biomarkers, neurological biomarkers, and autoimmune disease biomarkers and the various technologies include chemiluminescence, enzyme linked immunosorbent assay, fluorescence, multiplex, radioimmunoassay, and other technologies. The various applications involved are oncology diagnostics, cardiology diagnostics, infectious disease testing, endocrinology testing, autoimmune disease testing, neurology diagnostics, and drug discovery and development, and they are utilized by end users including clinical diagnostic laboratories, pharmaceutical research and development, contract research organizations, hospitals and clinics, and academic research institutes.

What Is The Biomarker-Based Immunoassays Market Growth Forecast?

The biomarker-based immunoassays market size is expected to see rapid growth in the next few years.It will grow to $11.55 billion by 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to rising demand for personalized medicine and precision diagnostics, increasing integration of ai and machine learning in biomarker analysis, growing adoption of multiplex and high throughput immunoassay technologies, expansion of point of care diagnostic testing in remote healthcare settings, increasing investment in pharmaceutical research and drug discovery applications.Major trends in the forecast period include ai driven biomarker interpretation and predictive disease modeling for enhanced diagnostic accuracy, multiplex immunoassay platforms enabling simultaneous detection of multiple biomarkers, cloud integrated immunoassay systems for centralized diagnostic data management, lab automation and robotic sample processing for high throughput immunoassay testing, next generation point of care immunoassay devices for rapid clinical diagnostics.

Global Biomarker-Based Immunoassays Market Segmentation

1) By Product: Consumables, Instruments And Analyzers, Reagents And Kits, Services 2) By Biomarker Type: Protein Biomarkers, Hormone Biomarkers, Cardiac Biomarkers, Cancer Biomarkers, Infectious Disease Biomarkers, Neurological Biomarkers, Autoimmune Disease Biomarkers 3) By Technology: Chemiluminescence, Enzyme Linked Immunosorbent Assay, Fluorescence, Multiplex, Radioimmunoassay, Other Technologies 4) By Application: Oncology Diagnostics, Cardiology Diagnostics, Infectious Disease Testing, Endocrinology Testing, Autoimmune Disease Testing, Neurology Diagnostics, Drug Discovery And Development 5) By End-User: Clinical Diagnostic Laboratories, Pharmaceutical Research And Development, Contract Research Organizations, Hospitals And Clinics, Academic Research Institutes Subsegments: 1) By Consumables: Pipette Tips, Microplates, Sample Containers, Microcentrifuge Tubes, Reagent Reservoirs, Disposable Pipettes 2) By Instruments And Analyzers: Enzyme Linked Immunosorbent Assay Analyzers, Chemiluminescence Immunoassay Analyzers, Fluorescence Immunoassay Systems, Multiplex Assay Platforms, Radioimmunoassay Instruments, Automated Immunoassay Analyzers 3) By Reagents And Kits: Enzyme Linked Immunosorbent Assay Kits, Chemiluminescence Immunoassay Reagents, Fluorescence Immunoassay Reagents, Multiplex Assay Kits, Radioimmunoassay Kits, Controls And Standards 4) By Services: Assay Development Services, Sample Testing Services, Data Analysis Services, Technical Support Services, Clinical Trial Support Services, Training And Consultation Services

What Is The Driver Of The Biomarker-Based Immunoassays Market?

The increasing incidence of oncology cases is expected to propel the growth of the biomarker-based immunoassays industry going forward.Oncology cases refer to the occurrence of cancers caused by abnormal and uncontrolled cell growth that can spread to different parts of the body.The incidence of oncology cases is rising primarily due to aging populations, as the risk of developing cancer increases significantly with age and longer life expectancy leads to a higher number of diagnosed cases.Biomarker-based immunoassays help the management of oncology cases by enabling early detection, precise monitoring of disease progression, and guiding personalized treatment decisions through accurate identification of cancer-specific biomarkers.For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022.Therefore, the increasing incidence of oncology cases is driving the growth of the biomarker-based immunoassays industry.

Key Players In The Global Biomarker-Based Immunoassays Market

Major companies operating in the biomarker-based immunoassays market are Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Eurofins Scientific SE, Bio-Rad Laboratories Inc., QIAGEN N. V., Tecan Trading AG, Autobio Diagnostics Co. Ltd., Promega Corporation, Sekisui Diagnostics LLC, Boditech Med Inc., Dynex Technologies Inc., NanoEntek Inc., J. Mitra & Co. Pvt. Ltd., ALPCO Diagnostics LLC, Micropoint Bioscience Inc., Coris BioConcept, MiCo BioMed Co. Ltd., Abionic SA, ANP Technologies Inc., Axela Inc., Epitope Diagnostics Inc., MedMira Inc., Nanomix Inc.

Global Biomarker-Based Immunoassays Market Trends and Insights

Major companies operating in the biomarker-based immunoassays market are focusing on developing innovative solutions such as, ultrasensitive immunoassay platforms to enable early and accurate detection of low-abundance biomarkers. Ultrasensitive immunoassay platforms are advanced diagnostic systems designed to detect extremely low concentrations of biomarkers with high precision and specificity, helping enable earlier disease detection, improved diagnostic accuracy, and better monitoring of disease progression compared to conventional assays. For instance, in July 2025, Spear Bio Inc., a US-based biotechnology company, launched SPEAR UltraDetect, a next-generation ultrasensitive immunoassay solution designed to enhance biomarker detection in neurodegenerative disease research. The platform utilizes proprietary homogeneous assay technology that eliminates the need for wash steps, unlike traditional heterogeneous immunoassays, enabling faster and more streamlined workflows. It is capable of detecting protein biomarkers at attomolar concentrations using as little as 1 µL of sample, significantly improving sensitivity and efficiency. The solution includes assays targeting key neurological biomarkers such as pTau217, pTau231, GFAP, and NfL, supporting early and accurate disease analysis.

What Are Latest Mergers And Acquisitions In The Biomarker-Based Immunoassays Market?

In July 2025, Alden Scientific Inc., a US-based healthcare technology company, acquired Oncimmune Germany GmbH for an undisclosed amount. With this acquisition, Alden Scientific Inc. aims to enhance its multi-omic and precision medicine capabilities by integrating advanced immunodiagnostics and biomarker discovery technologies, thereby strengthening its ability to analyze immune-mediated diseases and expand its data-driven health platform. Oncimmune Germany GmbH is a Germany-based healthcare technology company that specializes in providing immunodiagnostics and autoantibody biomarker discovery services through its proprietary platforms.

Regional Insights

North America was the largest region in the biomarker-based immunoassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biomarker-Based Immunoassays Market?

The biomarker-based immunoassays market consists of sales of rapid test kits, chemiluminescent immunoassay kits, multiplex assay kits, antibodies, reagents, lateral flow readers, and flow cytometers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

What is the Market Assessment and Strategic Outlook for the Biomarker-Based Immunoassays Industry?

The biomarker-based immunoassays market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker-based immunoassays industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

What is the Market Assessment and Strategic Outlook for the Biomarker-Based Immunoassays Market Report 2026?

The biomarker-based immunoassays market research report is one of a series of new reports from The Business Research Company that provides biomarker-based immunoassays market statistics, including biomarker-based immunoassays industry global market size, regional shares, competitors with a biomarker-based immunoassays market share, detailed biomarker-based immunoassays market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker-based immunoassays industry. This biomarker-based immunoassays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.